louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02611011: Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey
Official title: Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Preeclampsia
Keywords: Congo Red Dot Test
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2015-11-20
Enrollment: 198
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women attending Centre de Salud Beatriz Velasco de Aleman for health services

Brief summary: To determine if women can understand the instructions, carry out the test, and interpret the test results. Women will be recruited to complete a test instruction and comprehension assessment and a usability assessment.

Detailed description: To determine if women can understand the instructions, carry out the test, and interpret the test results. Women will be recruited to complete a test instruction and comprehension assessment and a usability assessment. Study participants will be a convenience sample of women seeking health services. Participants will first be asked to review the instructions for the Congo Red Dot Test and complete a short written questionnaire that assesses their comprehension of the test instructions. Participants will then be asked to perform the test using a test control and to interpret the results obtained by answering a second written questionnaire. After the woman performs the test, a healthcare provider will use a matched control to perform a second test.

Eligibility criteria: Inclusion Criteria:

* Eligible to consent for research
* Able to read Spanish well enough to read the test instructions
* Able to give informed consent

Exclusion Criteria:

* None

Primary outcomes:
measure: CRD Test Comprehension
timeFrame: within 5 minutes of reading test instructions
Secondary outcomes:
measure: CRD Test Usability
timeFrame: within 5 minutes of performing test
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Centro de Slaud Beatriz Velasco de Aleman
Study officials:
affiliation: Gynuity Health Projects
name: Beverly Winikoff, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02616211: An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Official title: An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adenocarcinoma of Lung
Lung Neoplasm
Cancer of Lung
Lung Cancer
Pulmonary Cancer
EGFR Genes
ALK Genes
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Foundation for Cancer Research
First posted: 2015-11-26
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen at the Mayo Clinic Rochester

Brief summary: Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.

Detailed description: In order to improve the treatment outcome for thoracic carcinomas after they become resistant to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for genomic analysis to identify novel somatic changes in critical genes and gene pathways that can potentially be targeted with therapy. The study team is also creating patient-derived xenografts to test drug efficacy and optimize personalized therapy for each patient.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Thoracic carcinoma tumors are positive for any targetable genetic alterations
* Have shown partial or no response, progression or recurrence while on or after gene targeted therapy by CT/PET scan
* Tumor is accessible for biopsy or surgery
* Expected life is 6 months or longer.

Exclusion Criteria:

* \< 18 years
* Not able to communicate in English

Primary outcomes:
measure: Identify the number of molecular changes in the recurrent tumor through molecular analysis with gene panels.
timeFrame: 1 Year
measure: Number of tumorgrafts from biopsies of the recurrent tumor grown and used for drug treatment selection based on genomic signatures.
timeFrame: 1 Year
Secondary outcomes:
measure: Recording turn-around-time
timeFrame: 1 year
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Jin Jen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01019811: Innervated Sensory Cross-Finger Flap
Official title: The Innervated Sensory Cross-finger Flap Based on the Dorsal Branch Artery for Reconstruction of Fingertip Degloving Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transplantation
Keywords: Cross-finger flap
finger injuries
fingertip reconstruction
proper digital artery
proper digital nerve.
Lead sponsor: The Second Hospital of Tangshan
Sponsor class: OTHER
First posted: 2009-11-25
Enrollment: 16
Sex: ALL
Minimum age (years): 12
Maximum age (years): 59
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to introduce a new operative technique for reconstruction of fingertip degloving injury.

Detailed description: Incidence of fingertip degloving injury is common and can result in functional morbidity. A cross-finger flap based on the dorsal branch artery (DBA) including sensory nerve is a useful reconstructive technique.In our modification, the innervated sensory flap is vascularized by the DBA, both its pedicle is narrow and its coverage is extended, the projecting tip of exposed distal phalanx of adjacent digits therefore can be wrapped.

Eligibility criteria: Inclusion Criteria:

* the fingertip degloving injury including the thumb;
* age between 12 and 59 years;
* no life-threatening associated injuries.

Exclusion Criteria:

* age greater than 60 years;
* smoking;
* Dupuytren's contracture;
* peripheral arterial disease and other vascular disorders.

Primary outcomes:
measure: static 2-point discrimination test and the range of motion are used for evaluation of outcomes
timeFrame: at least 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tangshan
country: China
facility: The Second Hospital of Tangshan
state: Hebei
Study officials:
References:
Clinical trial NCT03522311: Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function
Official title: Evaluation of 25-gauge Vitrectomy Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Proliferative Diabetic Retinopathy
Lead sponsor: Kyorin University
Sponsor class: OTHER
First posted: 2018-05-11
Enrollment: 251
Sex: ALL
Minimum age (years): 10
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The eyes with proliferative diabetic retinopathy

Brief summary: The surgical outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy has been evaluated by preoperative glycemic control and renal function

Detailed description: The purpose of this study is to evaluate the surgical outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy by preoperative glycemic control and renal function.

Eligibility criteria: Inclusion Criteria:

* The patients had25-gauge vitrectomy for proliferative diabetic retinopathy

Exclusion Criteria:

* The patients had hemodialysis , followed up less than 6 months, had vitrectomy for diabetic macular edema and macular ration but not macular detachment.

Primary outcomes:
measure: Visual acuity measurement
timeFrame: 6 months
Secondary outcomes:
measure: Presence of postoperative vitreous hemorrhage
timeFrame: 6 months
Other outcomes:
measure: Presence of postoperative retinal detachment
timeFrame: 6 months
Locations:
Study officials:
affiliation: Kyorin Eye Center
name: Makoto Inoue, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06245811: Inflammation Markers in Hyperemesis Gravidarum
Official title: Evaluation of the Relationship Between Hyperemesis Gravidarum (HEG) With Platelet Crit (PCT), Haemoglobin to Red Cell Distribution Width Ratio (HRR) and Neutrophil to Lymphocyte Ratio (NLR).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperemesis Gravidarum
Keywords: Hyperemesis gravidarum
Platelet criterion (PCT)
Hemoglobin/red cell distribution width ratio (HRR)
Neutrophil/lymphocyte ratio (NLR)
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2024-02-07
Enrollment: 215
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 213 pregnant women, including 102 pregnant women with hyperemesis gravidarum and 113 healthy pregnant women between 5-16 weeks of age, were included in the study.

Brief summary: In this study, the relationship between the severity of hyperemesis gravidarum (HEG) disease and subclinical inflammatory factors such as Platelet Crit (PCT), Hemoglobin/red cell distribution width ratio (HRR), Neutrophil/lymphocyte ratio (NLR), was investigated.

Detailed description: A total of 215 pregnant women, 102 with hyperemesis gravidarum and 113 healthy pregnant women, were included in the study. HEG patients were divided into three groups according to the modified PUQE classification: mild (n=38), moderate (n=32) and severe (n=32).

In our study, we proposed using a new prognostic marker for HEG patients. We think that our study will be a source for future studies on HEG.

Eligibility criteria: Inclusion Criteria:

* Healthy pregnant women over 18 years of age
* 5-16 weeks of gestation.

Exclusion Criteria:

Smoking, urinary tract infections, previously diagnosed psychological disorders, gastrointestinal disorders, multiple pregnancies, eating disorders, thyroid disorders, inflammatory disease, pregnancy with assisted fertilization technique.

Primary outcomes:
measure: The Pregnancy Unique Quantification of Emesis/Stomach scoring system
timeFrame: 2 months
Secondary outcomes:
measure: Body mass index
timeFrame: 2 months
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Yuzuncu Yil University, Faculty of Medicine
Study officials:
affiliation: Yuzuncu Yıl University
name: Kazım Uçkan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05069311: Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery
Official title: Effects of Multimodal Analgesia on Monocyte Chemoattractant Protein-1, Brain-derived Neurotrophic Factor, and RNA-124 Micro to Acute Pain in Patients Who Underwent Hysterectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammation
Inflammatory Response
Acute Pain
Chronic Pain
Lead sponsor: Udayana University
Sponsor class: OTHER
First posted: 2021-10-06
Enrollment: 62
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.


Eligibility criteria: Inclusion Criteria:

* Scheduled for elective hysterectomy
* American Society of Anesthesiologists (ASA) physical status 1 to 3

Exclusion Criteria:

* allergy to studied drugs
* history of chronic pain
* history of hepatitis, depression, peptic ulcer, or acute myocardial infarction
* receive intraoperative massive blood transfusion
* prolonged coagulation
* body mass index \>35 kg/m2
* patients with neurological deficits
* taking anti-platelet medications

Primary outcomes:
measure: Preoperative MCP-1
timeFrame: 1-hour before surgery
measure: Preoperative BDNF
timeFrame: 1-hour before surgery
measure: Preoperative MiRNA-124
timeFrame: 1-hour before surgery
measure: Postoperative MCP-1
timeFrame: 48-hours after surgery
measure: Postoperative BDNF
timeFrame: 48-hours after surgery
measure: Postoperative MiRNA-124
timeFrame: 48-hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Denpasar
country: Indonesia
facility: Sanglah General Hospital
state: Bali
Study officials:
References:
Clinical trial NCT04926311: Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder
Official title: Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Language Development Disorders
Speech and Language Disorder
Therapy
Keywords: Language Development Disorders
Speech and Language Disorder
Academic outcomes
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2021-06-15
Enrollment: 130
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients agreed to participate in the study will respond by phone to a questionnaire providing information on modalities of speech and langage intervention therapy, their course of school and academic studies, potentially associated developmental disorders and their management. Analysis will focused on the effects of speech and langage therapy modalities (intensity, age onset, duration), comorbidities and their management if concerned, special education resource teacher or specialized board-level support during the school trajectory on the school grade repetition in the patients of the study.

Brief summary: Children with Developmental Language Disorder (DLD) have many linguistic difficulties in syntax, lexicon, morphology and phonology. Frequently, they also present co-occurrent (or comorbidities) impairments which further impaired school learning. Thus, they have poor academic outcomes and many of these children have been maintained at least one time in a classroom, sometime more.

The purpose of this project is to determine which modalities of speech and language therapy are the more efficient on academic outcomes of children with DLD. The main modalities that will be studied are the duration of speech and language intervention, the age at which begins the intervention and the intensity (number of intervention sessions per week).


Eligibility criteria: Inclusion Criteria:

* patients Have been diagnosed in the University Hospital of Amiens-Picardie with a Developmental Language Disorder
* patients must be aged 12 or older,
* patients must be agreed answering the questionnaire

Exclusion Criteria:

* Children with a neurological pathology or handicap as epilepsy, cerebral palsy, sequelae of severe brain injury (traumatic or ischemic or inflammatory...)
* patients with a severe mental retardation
* patients with autism
* patients with bipolar illness
* patients with psychosis

Primary outcomes:
measure: Number of repeated school year according length of language therapy (number of days)
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
References:
Clinical trial NCT00869011: Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
Official title: Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Renal Cell Carcinoma
Keywords: Cancer
renal cell carcinoma
fatigue
exercise
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2009-03-25
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.


Eligibility criteria: Inclusion Criteria:

* 18 to 75 years
* Understanding of written German
* Treatment with Sunitinib
* Ability to walk

Exclusion Criteria:

* Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
* BMI \< 18 or \> 30

Primary outcomes:
measure: Fatigue
timeFrame: 12 weeks
Secondary outcomes:
measure: VO2max
timeFrame: 12 weeks
measure: Systolic and diastolic blood pressure (24 h)
timeFrame: 12 weeks
measure: Depression score
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30
Study officials:
References:
Clinical trial NCT00163111: A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
Official title: A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Candidiasis
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-13
Enrollment: 412
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients


Eligibility criteria: Inclusion Criteria:

* Patients with candidemia

Exclusion Criteria:

* Neutropenia

Primary outcomes:
measure: Sustained clinical response for 12 weeks from end of treatment
Secondary outcomes:
measure: Time to negative blood cultures
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02036411: Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B
Official title: Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: clomiphene citrate
amh
inhibin b
Lead sponsor: Bagcilar Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-01-15
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women receiving infertility treatment

Brief summary: 100mg clomiphene citrate used for ovulation induction. The investigators take blood sample at 3 and 10 days of menstruation and count AMH and inhibin B.

Detailed description: 100mg clomiphene citrate used for ovulation induction. The investigators take blood sample at 3 and 10 days of menstruation. AMH and inhibit B level will be measured in serum. We want to search relation of AMH, inhibin b and ovulation induction.

Eligibility criteria: Inclusion Criteria:

* Infertility treatment

Exclusion Criteria:

* Previous ovarian surgery
* Single functioning ovary

Primary outcomes:
measure: Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH level
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Bagcilar Training and Research Hospital
Study officials:
affiliation: Bagcilar Training and Research Hospital, Istanbul, Turkey.
name: TANER USTA, M.D
role: PRINCIPAL_INVESTIGATOR
References: